Therapeutic Response Statement (Sensitivity) Deprecated

This therapeutic response statement Supports the relationship that HER2-positive status confers therapeutic sensitivity to Trastuzumab in patients with Invasive Breast Carcinoma.

The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (IV) for reimbursement as a monotherapy treatment option for the treatment of patients with HER2 positive early breast cancer.

This statement is based on a regulatory approval from the Health Service Executive:

HER2 positive early breast cancer (EBC).

Citation

Trastuzumab (IV) Monotherapy - 21 days, 2026, version number 8, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6539/200_Trastuzumab_21days_BacgA2B.pdf

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database